drugset / Trial / NCT02017639

Sarilumab Effect on the Pharmacokinetics of Simvastatin

NCT02017639

Phase 1 Completed 19 enrolled Sanofi Regeneron Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelHealth-services research

Summary

Primary Objective: To evaluate the effect of a single 200 mg subcutaneous injection of sarilumab on the pharmacokinetics of simvastatin in patients with rheumatoid arthritis Secondary Objective: To describe the safety and efficacy (exploratory) of sarilumab

Timeline

Start
2014-01
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarilumab Monoclonal antibody 200 mg Subcutaneous
Subject Simvastatin Small molecule 40 mg Oral

Indications